EuMentis Therapeutics Plans to Initiate Phase 2 study of EM-221, a PDE10A Inhibitor, for Treatment of Tourette Syndrome
March 24, 2022
EuMentis Therapeutics, Inc. (“EuMentis” or the “Company”), a clinical-stage pharmaceutical company developing neurocircuit-selective medicines to treat neurodevelopmental disorders, announced today that it will initiate a phase 2 clinical study of EM-221 for the treatment of Tourette Syndrome.
Download PDF